

The Securities and Futures Commission of Hong Kong, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities nor it is calculated to invite any such offer or invitation. This announcement is not, and is not intended to be, an offer or sale of securities of The United Laboratories International Holdings Limited (聯邦制藥國際控股有限公司) (the “Company”) in the United States.

Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 4 June 2007 issued by the Company (the “Prospectus”).



聯邦制藥國際控股有限公司

The United Laboratories International Holdings Limited

(a company incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

STABILISATION ACTIONS AND END OF STABILISATION PERIOD

Summary

The Company announces that the stabilisation period in connection with the Share Offer ended on 7 July 2007.

The stabilisation actions undertaken during the stabilisation period were (i) the over-allocations of 45,000,000 Shares made in the International Placing and (ii) the exercise in full by the Global Coordinator on 22 June 2007 of the Over-allotment Option referred to in the Prospectus in respect of 45,000,000 Sale Shares, which were used to cover over-allocations in the International Placing.

The Company makes this announcement pursuant to Section 9(2) of the Securities and Futures (Price Stabilising) Rules (Cap. 571W of the Laws of Hong Kong) and announces that the stabilisation period in connection with the Share Offer ended on 7 July 2007.

The stabilisation actions undertaken during the stabilisation period were (i) the over-allocations of 45,000,000 Shares made in the International Placing and (ii) the exercise in full by the Global Coordinator on 22 June 2007 of the Over-allotment Option referred to in the Prospectus in respect of 45,000,000 Sale Shares (the “**Over-allotment Shares**”). Pursuant to the exercise of the Over-allotment Option, the Selling Shareholder sold the Over-allotment Shares to the Global Coordinator at HK\$2.75 per Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.004% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Share Offer. The Over-allotment Shares were used to cover over-allocations in the International Placing.

Details of the exercise of the Over-allotment Option are more particularly described in the Company's announcement dated 22 June 2007.

By order of the Board
Choy Kam Lok
Chairman

As at the date of this announcement, the executive directors of the Company are Mr. Choy Kam Lok, Ms. Peng Wei and Mr. Leung Wing Hon; the non-executive Director is Ms. Choy Siu Chit; and the independent non-executive Directors are Mr. Heng Kwo Seng, Mr. Huang Bao Guang and Mr. Song Ming.

Hong Kong, 12 July 2007